Milrinone Lactate

乳酸米力农

Report date: 2022/12/23 18:00:08
NME

Base Information

Drug NameMilrinone Lactate
Drug Alias Namemilrinona甲氰吡酮二联吡啶酮milrinonum米利酮 +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action3',5'-cyclic phosphodiesterase inhibitors
Targets3',5'-cyclic phosphodiesterase
Therapy Area/IndicationsHernias, Diaphragmatic, CongenitalVentricular Dysfunction, RightShock, Cardiogenic +[13] 
Global Approved IndicationsHeart Failure
Approved Indications in ChinaHeart Failure
Original Approved Country/TerritoryUnited States
Original Approved Date1987/12/31
Country/TerritoryCanadaUnited StatesThailand +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentThe University Of ChicagoNational Heart, Lung, And Blood Institute (Nhlbi) +[7] 
Inactive CompaniesIndiana UniversityMontreal Heart InstituteSanofi-Aventis U.S. Llc +[6] 
Active IndicationsHernias, Diaphragmatic, CongenitalShock, CardiogenicHeart Failure +[10] 
Inactive IndicationsVentricular Dysfunction, RightMitral Valve InsufficiencyVasospasm, Intracranial

Other Information

ATC CodeC01CE02
Related LinksWikipediaDrugBankKEGG